Regeneron Pharmaceuticals Surges to 91st in Trading Volume with $740 Million Day

On June 6, 2025, Regeneron Pharmaceuticals (REGN) saw a trading volume of $740 million, ranking 91st in the day's stock market activity. The company's stock price increased by 2.10%.

Regeneron Pharmaceuticals has announced that its drug Eylea has been approved by the FDA for the treatment of diabetic retinopathy. This approval is expected to significantly boost the company's revenue and market share in the ophthalmology sector. Eylea is already a leading treatment for age-related macular degeneration and wet AMD, and this new indication will further solidify its position in the market.

In addition to the FDA approval, Regeneron has also reported positive results from its Phase 3 clinical trial for its new drug, REGN4210. The trial, which was conducted on patients with moderate to severe atopic dermatitis, showed that the drug was effective in reducing symptoms and improving the quality of life for patients. This positive news has generated significant interest from investors and analysts, who see the potential for REGN4210 to become a blockbuster drug in the dermatology market.

Regeneron's strong pipeline of innovative drugs and its commitment to research and development have positioned the company as a leader in the biotechnology industry. With the approval of Eylea for diabetic retinopathy and the positive results from the Phase 3 trial for REGN4210, Regeneron is well-positioned to continue its growth trajectory and deliver value to its shareholders.